Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

Allergic Conjunctivitis Clinical Trial

— TX-SMILE  

Official title:

Texan Allergy & Sinus Center Mountain Cedar Intra-Lymphatic Immunotherapy Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03682965
• Other study ID #: TASC-ILIT-MC-2018
• Status: Completed
• Phase: Phase 2
• Start date: September 28, 2018
• Est. completion date: April 29, 2019

Study information

• Verified date: March 2021
• Source: Texan Allergy & Sinus Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

TX-SMILE is an investigator-initiated, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of intra-lymphatic administration of an approved allergenic extract for the immunotherapy treatment of allergic rhinitis and conjunctivitis due to pollen from the conifer Mountain Cedar.

Description:

TX-SMILE is an investigator-initiated, multi-center, randomized, double-blind, parallel-group, placebo-controlled study to evaluate the efficacy, safety, and tolerability of an alternative injection site and associated adjustments to dosing and treatment regimen for allergen immunotherapy with a commercially-available, FDA-approved allergenic extract for the immunotherapy treatment of allergic rhinitis and conjunctivitis due to pollen from the conifer Mountain Cedar (Juniperus ashei). The purpose of this study is to evaluate the effect of a three-dose treatment series of ultrasonography-guided, intra-lymphatic immunotherapy injections over a two-month period prior to the start of the 2018-2019 Mountain Cedar allergy season in central Texas. Patients will be evaluated for safety and tolerability during the treatment period and for efficacy during the 2018-2019 Texas Mountain Cedar pollen season.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 21
• Est. completion date: April 29, 2019
• Est. primary completion date: March 6, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Both male and female adult patients with a history of Season Allergic Rhinitis (SAR) with bothersome symptoms due to Mountain Cedar pollinosis confirmed using the Modified Quantitate Test (MQT; defined as a wheal greater than or equal to 3 millimeters larger than the diluent control)

2. Patients must be willing to provide written, informed consent

3. Patients must be willing and able to comply with study procedures

4. Women of childbearing potential must agree to use an acceptable form of contraception during the trial

Exclusion Criteria:

1. Patients less than 18 years of age

2. Clinically-significant chronic sinusitis, as determined by the investigator

3. History of anaphylaxis during Mountain Cedar skin prick testing

4. Participation in another clinical trial or use of an experimental medication within 30 days of enrollment

5. Medically significant co-morbidities that, in the opinion of the investigator, place

the subject at increased risk during the study, including but not limited to:

1. Autoimmune diseases, other than allergic rhinitis (AR), stable allergic asthma, eczema and food sensitivities

2. Pulmonary or respiratory diseases other than stable asthma

3. Cancer other than basal cell carcinoma

4. Coronary artery disease or hypertension treated with beta-blockers

5. Clinically significant impairment of renal or hepatic function

6. Use of concomitant medications that, in the opinion of the investigator, may reduce the effectiveness of rescue treatments for anaphylaxis (e.g. beta-blockers) or alter the immune response to allergen immunotherapy (e.g., immunosuppressants, systemic corticosteroids)

7. Previously completed immunotherapy for Mountain Cedar pollinosis, that in the opinion of the investigator would interfere with the assessment or treatment of the patient

8. Inability to access suitable lymph nodes for intralympahtic injections

9. Plans to leave the area for a significant period of the upcoming Mountain Cedar pollen season

10. Pregnant or lactating females

Related Conditions & MeSH terms

• Allergic Conjunctivitis
• Allergic Rhinitis Due to Tree Pollen
• Allergic Rhinoconjunctivitis
• Conjunctivitis
• Conjunctivitis, Allergic
• Rhinitis
• Rhinitis, Allergic

Intervention

Biological:
• Intra-lymphatic allergenic extract
Mountain Cedar pollen allergenic extract is an FDA-approved, commercially available product for diagnosis and hypo-sensitization treatment of allergies. The labeled use is deep subcutaneous or percutaneous injection. Hyposensitization treatment is typically a series of 30 - 70 injections over 3 - 5 years into the upper aspect of the arm. This investigation is a proof-of-concept study to evaluate an alternative hyposensitization regimen of 3 injections directly into an inguinal lymph node.
• Intra-lymphatic placebo
The control group will receive a regimen of 3 injections of diluent (placebo) directly into an inguinal lymph node on the same schedule as the active treatment group.

Locations

Country	Name	City	State
United States	Texan Allergy & Sinus Center	Austin	Texas
United States	Texan Allergy & Sinus Center	Grapevine	Texas
United States	Texan Allergy & Sinus Center	San Antonio	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Christopher Thompson, MD

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Total Number of Rescue Inhaler Uses by Patients With Asthma	Relative use of rescue inhalers by patients with comorbid asthma between active and placebo groups during the 2018-2019 Mountain Cedar pollen season.	Up to 4 month
Primary	Average Daily Total Combined Score (TCS)	The TCS is the preferred endpoint for rhinoconjunctivitis as recommended by the European Academy of Allergy and Clinical Immunology. Scoring of the TCS is from 0 to 38 on each day that it is assessed. The TCS is the sum of the symptom scores for "runny nose", "stuff nose", "sneezing", "itchy nose", "gritty/itchy eyes", and "watery eyes" rated from no symptoms = 0 to severe symptoms = 3 plus the score for use of rescue medications for allergy symptoms 6 points for oral antihistamine, 6 points for eye drops, and 8 points for a nasal corticosteroid. Thus, a lower score represents fewer symptoms and associated need for allergy medication, while a higher score reflects more severe symptoms and the use of medication to treat symptoms. The TCS will be measured during the 2018-2019 Mountain Cedar pollen se	Up to 4 months
Secondary	Number of Peak Pollen Season Days With a Lower Group Average Total Combined Score	Evaluated during the 2018-2019 Texas Mountain Cedar allergy season. The number of days with a lower group average Total Combined Score, comparatively, in each Arm/Group are reported. Scoring of the TCS is from 0 to 38 on each day that it is assessed.The TCS is the sum of the symptom scores for "runny nose", "stuff nose", "sneezing", "itchy nose", "gritty/itchy eyes", and "watery eyes" rated from no symptoms = 0 to severe symptoms = 3 plus the score for use of rescue medications for allergy symptoms 6 points for oral antihistamine, 6 points for eye drops, and 8 points for a nasal corticosteroid. Thus, a lower score represents fewer symptoms and associated need for allergy medication, while a higher score reflects more severe symptoms and the use of medication to treat symptoms.	Assessed up to 4 months, number of actual peak pollen season days was 27
Secondary	Patient Reported Pain or Discomfort Following Intra-lymphatic Injections	Patient reported pain will be measured immediately after ILIT procedure using the Numeric Rating Scale 11 (NRS-11 rating scale). The NRS-11 asks patients to rate their pain on a scale from 0 (no pain or discomfort) to 11 (worst possible pain).	Immediately after the ILIT procedure
Secondary	Patient-reported Treatment Satisfaction at the End of Study	Percentage of patients reporting satisfaction with their treatment	Up to 4 months
Secondary	Percentage Change in Allergen-specific Serum IgE	Percentage change in allergen-specific serum IgE from baseline to the end-of-study visit between active ILIT and placebo.	Assessed prior to the first injection and to 4-8 weeks after the end of the 2018-2019 pollen season
Secondary	Total Safety Score (TSS) for Active and Placebo Treatment Groups	The total safety score is a is based on World Allergy Organization grading for allergic reactions. Following allergen or placebo exposure via intra-lymphatic injection, patients are monitored for local and systemic allergic reactions for up to 60 minutes post-procedure. At each exposure, a score is rated on a scale from none = 0, local reactions only = 1, mild systemic reactions (WAO Grade 1/2) = 2, moderate systemic reaction (WAO Grade 3) = 3, and severe systemic reaction (WAO grade 4) = 4. The total safety score for each group is the sum of the individual scores of each patient across all three treatments (exposures). Thus, the subject may have a score from 0 to 12 with 0 reflecting no allergic reaction to the allergen and 12 reflecting severe allergic reactions, and the TSS for a group is the sum for all patients in the group. The TSS is used to elicit and grade adverse events of interest rather than for statistical analysis.	8 weeks
Secondary	Number of Subjects Who: Experienced Anaphylaxis, Were Treated With Epinephrine, or Experienced Any Other Treatment-emergent SAE Within 60 Minutes of Any of Three Planned ILIT Procedures	To evaluate the safety of ILIT for Mountain Cedar pollinosis relative to placebo control based on the proportion of subjects receiving allergenic extract versus the proportion of subjects receiving placebo that: experience anaphylaxis, or; are treated with epinephrine, or; experience any other treatment-emergent, serious adverse event (SAE) within 60 minutes of any of the three planned ILIT procedures.	8 weeks